The Effect of GLP-1 Receptor Agonists on Outcomes in Metastatic Renal Cell Carcinoma Patients Undergoing Immune Checkpoint Inhibitor Therapy
GLP-1 agonists in mRCC patients showed 51% lower mortality and reduced immune toxicity with checkpoint inhibitors in 994-patient analysis.
